Related Experiment Video

Updated: May 22, 2026

Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts
11:11

Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts

Published on: December 17, 2016

In vivo gene delivery by nonviral vectors: overcoming hurdles?

Yuan Zhang1, Andrew Satterlee, Leaf Huang

  • 1Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7571, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 25, 2012
PubMed

Insights

Systemic delivery of cancer gene therapeutics faces significant hurdles. This review explores nonviral vector strategies to overcome in vivo delivery challenges for effective cancer gene therapy.

Area of Science:

  • Oncology
  • Gene Therapy
  • Biotechnology

Background:

  • Cancer gene therapeutics offer significant promise but face major delivery challenges.
  • Efficient in vivo delivery to targeted tumor cells, especially systemically, remains a critical barrier.

Purpose of the Study:

  • To review systemic in vivo gene delivery for cancer therapy using nonviral vectors.
  • To summarize existing delivery barriers and strategies for overcoming them.
  • To discuss current progress and safety considerations in nonviral vector design.

Main Methods:

  • Literature review of nonviral vector-based gene delivery systems for cancer therapy.
  • Analysis of in vivo delivery barriers and requirements.
  • Evaluation of current nonviral vector designs and their safety profiles.

Main Results:

  • Nonviral vectors are being actively developed to address systemic gene delivery challenges in cancer.
  • Various strategies exist to overcome identified delivery barriers.
  • Progress in nonviral vector design shows promise, but safety remains a key consideration.

Conclusions:

  • Overcoming systemic in vivo delivery barriers is crucial for advancing cancer gene therapeutics.
  • Nonviral vectors represent a promising avenue for improving cancer gene therapy efficacy and safety.
  • Continued research into nonviral vector design and safety is essential for clinical translation.

More Related Videos

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.